Melanoma Skin Cancer: Will the Drugs in the Pipeline Deliver?

2,970 views

Published on

The incidence of melanoma at a global level is increasing faster than the other types of cancer, with an approximate doubling of rates every 10 to 20 years in countries with Caucasian (light-skinned) populations. The presentation gives an overview of Melanoma skin cancer drugs in the pipeline.

Published in: Business, Health & Medicine
0 Comments
3 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
2,970
On SlideShare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
54
Comments
0
Likes
3
Embeds 0
No embeds

No notes for slide

Melanoma Skin Cancer: Will the Drugs in the Pipeline Deliver?

  1. 1. Melanoma Skin Cancer: Will the Drugs in the Pipeline Deliver? Ranjith Gopinathan, Industry Analyst Healthcare Practice May 25,2010 1
  2. 2. Disclaimer • Frost & Sullivan takes no responsibility for the incorrect information supplied to us by manufacturers or users • Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation • No part of this Research Service may be given, lent, resold or disclosed to non-customers without written permission • Furthermore, no part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the permission of the publisher • For information regarding permission, write to: Frost & Sullivan 4 Grosvenor Gardens Sullivan House London SW1W 0DH The United Kingdom © 2010 Frost & Sullivan. All rights reserved. This document contains highly confidential information and is the sole property of Frost & Sullivan. No part of it may be circulated, quoted, copied or otherwise reproduced without the written approval of Frost & Sullivan. 2
  3. 3. Certification • We hereby certify that the views expressed in this research service accurately reflect our views based on primary and secondary research with industry participants, industry experts, end users, regulatory organizations, financial and investment community, and other related sources • In addition to the above, our robust in-house forecast & benchmarking models along with the Frost & Sullivan Decision Support Databases have been instrumental in the completion this research service • We also certify that no part of our analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this service 3
  4. 4. Focus Points Skin Cancer : Melanoma– Key Facts 1 Patient Forecasts 2 3 Market Drivers and Restraints 4 Current Drug Therapies for Melanoma 5 Revenue Forecasts 6 Pipeline Analysis - Melanoma 4
  5. 5. Skin Cancer : Melanoma– Key Facts There are two main types of skin cancer: •Melanoma •Non-melanoma (Basal cell carcinoma, Squamous cell carcinoma) Other types of Skin Cancer: •Kaposi sarcoma (KS) •Merkel cell carcinoma (MCC) •Intraocular (Eye) Melanoma •Dermatofibrosarcoma protuberans (DFSP) •Sebaceous gland carcinoma (SGC) • The incidence of melanoma at a global level is increasing faster than the other types of cancer, with an approximate doubling of rates every 10 to 20 years in countries with Caucasian (light-skinned) populations. • Melanoma is the second most common cancer in the age group of 15 to 34 years. • Australia and New Zealand leads the world with world age-standardised rate between 30-40 cases per 100,000 population affected by skin cancer. •Melanoma is curable when it is detected during the early stages. Surgery is common treatment for early stage melanoma. •Melanoma is rare in non-white populations. 5
  6. 6. Patient Forecasts 6
  7. 7. Skin Cancer: Incidence and Mortality (World), 2006-2016 Note: The incidence post 2009 has been calculated based on population statistics. The figures do not take into account changes in diagnosis or other external factors. 7
  8. 8. Melanoma: Incidence and Mortality (United States, EU, Australia), 2006-2016 8
  9. 9. Current Drug Therapies for Melanoma Intron A (Interferon Alfa - 2B) Schering-Plough Treatment Area: Metastatic Melanoma Approval Status: Approved in 1987 (US FDA) Patent Expiry: 2002 Proleukin or Aldesleukin( IL-2, Interleukin 2) Novartis Approval Status: Approved in 1998 (US FDA) Treatment Area: Metastatic melanoma Chemotherapy DTIC-Dome (Dacarbazine) Bayer Approval Status: Approved in 1975 (US FDA) Treatment Area: Metastatic melanoma Generics: Available 9
  10. 10. Skin Cancer Therapeutics Market: Market Drivers Ranked in Order of Impact (World), 2010-2016 10
  11. 11. Skin Cancer Therapeutics Market: Market Restraints Ranked in Order of Impact (World), 2010-2016 11
  12. 12. Revenue Forecasts 12
  13. 13. Melanoma Therapeutics Market: Revenue Forecasts (World), 2006-2016 Note: • Future revenue potential of promising drug candidates which are currently in pipeline are also considered in the revenue forecasts. • Many of the drugs for cancer are indicated for more than one therapeutic indication. Publicly available information tends to combine all indications when sales figures are reported. Therefore, estimations and primary research were used to arrive at the Melanoma therapeutics revenue forecasts. In addition, the revenue estimations have been cross-validated with the market participants. 13
  14. 14. Melanoma Therapeutics Market: Revenue Forecasts (United States), 2006-2016 14
  15. 15. Melanoma Therapeutics Market: Revenue Forecasts (European Union), 2006-2016 15
  16. 16. Melanoma Therapeutics Market: Revenue Forecasts (Rest-of-World), 2006-2016 16
  17. 17. Pipeline Analysis - Melanoma Drug Name Developers Ipilimumab Bristol-Myers Squibb/ Medarex PLX4032 Roche/ Plexxikon Allovectin-7 Vical/ AnGes Genasense (oblimersen) Genta / Sanofi-Aventis Abraxane Abraxis BioScience/ AstraZeneca Mvax Avax Technologies BioVex Limited /Symbion Research OncoVEX International Gleevec (imatinib mesylate) Novartis Nexavar Bayer/ Onyx AS1409 Antisoma Adoptive cell transfer (ACT) therapy Sheba Medical Center Note: The above drugs pipeline list includes only, some of the most promising drugs in development and may not necessarily include all (promising) drugs in development for melanoma. 17
  18. 18. Next Steps Request a strategic approach document for a Growth Partnership Service or Growth Consulting Service to support you and your team to accelerate the growth of your company. (myfrost@frost.com) +44 (0)20 7343 8383 Join us at our annual Growth, Innovation and Leadership 2010: A Frost & Sullivan Global Congress on Corporate Growth London, United Kingdom (www.gil-global.com) Register for the next Chairman’s Series on Growth: Accelerating Growth Through Vertical Market Expansion: A How-To Primer 16 June 2010 10:00 AM BST (www.frost.com/growthEU) Register for Frost & Sullivan’s Growth Opportunity Newsletter and keep abreast of innovative growth opportunities (www.frost.com/news) 18
  19. 19. Your Feedback is Important to Us What would you like to see from Frost & Sullivan? Growth Forecasts? Competitive Structure? Emerging Trends? Strategic Recommendations? Other? Please inform us by taking our survey. 19
  20. 20. Frost & Sullivan on Twitter and Facebook Find us @Frost_Sullivan on Twitter Become a fan of Frost & Sullivan on Facebook 20
  21. 21. For Additional Information Katja Feick Noel Anderson Corporate Communications European Vice President Healthcare New Business Development 0049 (0) 69 7703343 +44 (0)207 343 8389 katja.feick@frost.com noel.anderson@frost.com Siddharth Saha Program Director Healthcare – Medical Technologies +44 (0) 207 343 8374 ssaha@frost.com 21

×